Compare GMTL & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMTL | SPRY |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.7M | 400.8M |
| IPO Year | 2024 | 2020 |
| Metric | GMTL | SPRY |
|---|---|---|
| Price | $5.40 | $3.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $25.50 | $24.33 |
| AVG Volume (30 Days) | 328.2K | ★ 1.5M |
| Earning Date | 11-14-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $52.57 |
| Revenue Next Year | N/A | $45.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.58 | $3.53 |
| 52 Week High | $22.21 | $13.15 |
| Indicator | GMTL | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 32.05 | 33.85 |
| Support Level | $4.58 | N/A |
| Resistance Level | $13.84 | $4.55 |
| Average True Range (ATR) | 0.63 | 0.24 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 27.10 | 11.60 |
Guardian Metal Resources PLC is mainly involved in the exploration and exploitation of mineral resources in the U.S. The group operated as a single operating and reportable segment, being the exploration and evaluation of mineral resources in Nevada, United States. Its projects are Pilot Mountain Project located in Nevada; Tempiute Project Located in south-central Nevada; Golconda Summit Project located in Nevada; Garfield Project located in Nevada; Kibby Basin Lithium Project located in Nevada; and Stonewall Project located in Nevada.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.